Why the study?
To examine the prevalence and factors associated with postmarketing communications by the US FDA regarding cardiovascular events associated with anticancer therapy.
This study examines the prevalence and factors associated with FDA postmarketing communications regarding the cardiovascular safety of contemporary anticancer therapies.
Answers are grounded in this paper and cite their sources.
Postmarketing FDA CV safety signals affect ~26% of anticancer therapies; leaves open optimal surveillance and risk mitigation strategies.
This cohort study examines the prevalence and factors associated with postmarketing communications by the US Food and Drug Administration about cardiovascular events associated with anticancer thearpy.
No takes yet. Share an insight, caveat, or question.
Bonsu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: